Legal Action Update for Actinium Pharmaceuticals Shareholders

Author: Evelyn Baker Updated: 04-21-2025 05:59 AM

Upcoming Class Action Notice for Actinium Pharmaceuticals Shareholders

The Gross Law Firm has issued a significant notice for shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). This notice pertains to individuals who may have purchased shares during a specified class period and encourages them to reach out regarding potential participation in a class action lawsuit.

Important Class Action Details

Shareholders of ATNM are invited to explore their options for potential recovery. Those interested in filing a claim can do so even if they are not appointed as lead plaintiffs. It is important for especially those who acquired shares within the relevant time frame to make their voices heard.

Class Period and Allegations

The class period for this action spans from October 31, 2022, to August 2, 2024. The allegations indicate that the defendants may have issued misleading statements regarding the company’s Phase 3 Sierra trial data, which are essential for obtaining the FDA's approval of their targeted radiotherapy, Iomab-B BLA. Such misleading information raises concerns about the integrity of the data presented to both shareholders and regulatory bodies.

Deadline for Participation

It is imperative for potential claimants to be aware of the upcoming deadline on May 27, 2025. This timeline stresses the urgency for shareholders, prompting them to register their details if they wish to stand for their rights in the class action.

Next Steps for Interested Shareholders

Once shareholders register, they will receive updates and monitoring of the case's progress through portfolio software. This offers peace of mind to investors, ensuring that they remain informed throughout the legal proceedings without incurring any costs for participation.

Why Choose The Gross Law Firm?

The Gross Law Firm has established itself as a leading entity in handling class action lawsuits, particularly for those affected by misinformation and fraudulent practices. Their commitment to investor rights is reflected in their rigorous approach to holding companies accountable. They represent a wide array of investors looking to recover losses stemming from misleading statements or omissions that inflate stock values.

Contact Information

For specific inquiries or to learn more about participating in the class action, shareholders can reach out through the provided contact details. The Gross Law Firm is located at 15 West 38th Street, 12th Floor, New York, NY 10018. Interested parties can phone at (646) 453-8903 for further assistance.

Frequently Asked Questions

1. What is the purpose of this class action?

This class action aims to hold Actinium Pharmaceuticals accountable for any misleading information that may have affected shareholder investments.

2. How can I participate in the class action?

Shareholders can participate by registering their information with The Gross Law Firm before the deadline of May 27, 2025.

3. Do I need to be a lead plaintiff to join?

No, becoming a lead plaintiff is not mandatory for participation or potential recovery.

4. Is there a cost to participate in the class action?

No, there is no cost or obligation to join the class action.

5. How will I be updated on the case's progress?

Registered shareholders will receive updates via a portfolio monitoring system that tracks the case's developments.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.